Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALB | P02768 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11964628 | 1.00 | CCKBR (0.61) | CCKBRMEN1LMNAALBKMT2A | |
| SCHEMBL3234690 | 0.92 | CCKBR (0.55) | CCKBRMEN1LMNAALBKMT2A | |
| SCHEMBL3229900 | 0.91 | CCKBR (0.61) | CCKBRMEN1LMNAALBKMT2A | |
| SCHEMBL3244364 | 0.90 | CCKBR (0.59) | CCKBRMEN1LMNAALBKMT2A | |
| SCHEMBL4100434 | 0.89 | CCKBR (0.54) | CCKBRMEN1LMNAALBKMT2A | |
| SCHEMBL608045 | 0.89 | CCKBR (0.54) | CCKBRMEN1LMNAALBKMT2A | |
| SCHEMBL11982411 | 0.89 | CCKBR (0.46) | CCKBRMEN1LMNAALBKMT2A | |
| SCHEMBL2264610 | 0.89 | CCKBR (0.60) | CCKBRMEN1LMNAALBKMT2A | |
| SCHEMBL607277 | 0.88 | CCKBR (0.59) | CCKBRMEN1LMNAALBKMT2A | |
| SCHEMBL11964637 | 0.88 | CCKBR (0.61) | CCKBRMEN1LMNAALBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274197-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-10-17 | — | — | US | claimed |
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | CCKBR 1128/4885MEN1 4607/4885LMNA 2002/4885 |
| US-20130274197-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | CCKBR 1128/4885MEN1 4607/4885LMNA 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.